Body contouring: A multibillion-dollar market

Fat removal for aesthetic purposes is a very significant market. Many people have stubborn fat deposits that do not respond to diet and exercise. The aesthetic market is historically lucrative—a tremendous profit opportunity in point-of-care treatments involving no surgery and no significant side effects.

RZL-012 for reduction of abdominal fat

In a double-blind placebo-controlled Phase 2a study, RZL-012, was injected into abdominal fat of volunteers having a BMI of 30–35.

Subcutaneous fat mass ratio was reduced by 15–20% vs vehicle (placebo) treated subjects.

RZL-012 for reduction of submental fat study –
A single blind placebo controlled Phase 2a study

RZL-012 was injected into the submental of healthy volunteers and reduced submental fat volume 84 days after injection.

Day 0


Day 84

a noticeable reduction in submental fat 84 days after injection.